The Long-term Outcome of Hepatitis B Infection in Hemodialysis Patients

Harnett, John D.; Parfrey, Patrick S.; Kennedy, Michael J.; Zeldis, Jerome B.; Steinman, Theodore I.; Rd, Guttmann

doi:10.1016/s0272-6386(88)80151-3

Cited by 50 publications

(30 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been suggested that patients who receive low initial infecting viral dose [15] and manifest only a mild disease [16] initially are most likely to develop persistent HBsAg infection. The risk of an HBsAg-positive dialysis patient remaining positive indefinitely increases with the duration of HBsAg positivity [17]. Seroconversion to HBsAgnegative status occurs in less than 10-20% of HD patients, especially after five months of antigenemia [17].…”

Section: Natural History Of Hbv Infection In Dialysis Patientsmentioning

confidence: 99%

“…The risk of an HBsAg-positive dialysis patient remaining positive indefinitely increases with the duration of HBsAg positivity [17]. Seroconversion to HBsAgnegative status occurs in less than 10-20% of HD patients, especially after five months of antigenemia [17]. HBsAg-positive individuals who become HBsAg-negative may develop antibody for surface antigen of the HBV (anti-HBs) or hepatitis B core (anti-HBc).…”

Section: Natural History Of Hbv Infection In Dialysis Patientsmentioning

confidence: 99%

“…The few reports [20][21][22][23] evaluating the histology of liver disease in hemodialysis (HD) patients showed that they tend to develop benign rather than cancerous liver lesions. However, compared with patients without end-stage renal disease, their course of HBV-related liver disease may be worse [17] with progression to cirrhosis not uncommon [21]. Hepatitis B infection in dialysis patients is less aggressive than it is in kidney transplant recipients; a number of reports [24][25][26][27] have demonstrated the long-term adverse effects of the chronic hepatitis B carrier state on that population.…”

Section: Natural History Of Hbv Infection In Dialysis Patientsmentioning

confidence: 99%

See 2 more Smart Citations

Hepatitis B Virus Infection in Dialysis Patients

Fabrizi¹,

Martin²

2000

Am J Nephrol

View full text Add to dashboard Cite

Section: Natural History Of Hbv Infection In Dialysis Patientsmentioning

confidence: 99%

Section: Natural History Of Hbv Infection In Dialysis Patientsmentioning

confidence: 99%

Section: Natural History Of Hbv Infection In Dialysis Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis B Virus Infection in Dialysis Patients

Fabrizi¹,

Martin²

2000

Am J Nephrol

View full text Add to dashboard Cite

“…In addition, infected patients have an increased tendency to develop chronic hepatitis and also to be a potential reservoir for its transmission (Goldbloom & Reed 1980, Harnett et al 1988.…”

mentioning

confidence: 99%

[No Title Available]

Souza

Luz²,

Teles

et al. 2003

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

“…The uremic milieu with related altered immunocompetence decreases the response to vaccinations 17 and promotes the maintenance of HBV or HCV replication. 18,19 These uremia-related activities may diminish the expression of genetic effects on the clinical parameters tested in the present study. Moreover, the association between IFNL3 polymorphisms and response to HBV vaccination was not studied in individuals under nonuremic or at 95°C for 15 minutes to activate HOT FIREPol DNA polymerase, followed by 50 amplification cycles of denaturation at 95°C for 10 seconds, annealing at 61°C for 10 seconds, and elongation at 72°C for 15 seconds.…”

Section: 4mentioning

confidence: 76%

Effect of interferon λ3 gene polymorphisms, rs8099917 and rs12979860, on response to hepatitis B virus vaccination and hepatitis B or C virus infections among hemodialysis patients

Grzegorzewska¹,

Jodłowska²,

Mostowska³

et al. 2015

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

IntroductIon The higher prevalence and risk of hepatitis B virus (HBV) or hepatitis C virus (HCV) infections are still observed in hemodialysis (HD) patients compared with healthy people. Interferons (IFNs) are known for their involvement in immune response. The addition of IFN-λ3 to immunization in animal models was shown to increase the immune response of T helper-1 cells.objectIves We studied whether polymorphisms of the IFN-λ3 gene (IFNL3) might be associated with the development of antibodies to HBV surface antigen [anti-HBs] in response to the HBV vaccination or HBV infection as well as spontaneous resolution of HCV infection in HD patients. PAtIents And methodsThe HD group consisted of 806 individuals without a history of HBV or HCV infection (of whom 672 developed anti-HBs in response to the HBV vaccination), 241 HBV-infected patients (of whom 186 developed anti-HBs), and 63 HCV-infected patients (including 39 HCV RNA-positive subjects). All patients were genotyped for IFNL3 rs8099917 and rs12979860 polymorphisms using a high-resolution melting curve analysis.results The comparison of responders and nonresponders to HBV vaccination revealed no significant differences in the IFNL3 genotype distribution. In HBV-infected patients, the differences in the distribution of IFNL3 variants between anti-HBs-negative and anti-HBs-positive patients were also nonsignificant. Spontaneous HCV clearance was significantly less common in the carriers of the rs8099917 allele G or rs12979860 allele T, while the CT rs12979860_rs8099917 haplotype was more frequent (P = 0.02) in patients showing spontaneous HCV clearance.conclusIons In HD patients, the IFNL3 polymorphisms do not affect anti-HBs development in response to HBV infection or vaccination, but might be involved in the resolution of HCV infection. 895uremic conditions. Therefore, we aimed to show whether the SNPs of IFNL3 might be associated with the development of antibodies to HBV surface antigen (anti-HBs) in response to HBV vaccination or infection as well as with spontaneous HCV clearance in HD patients. PAtIents And methods Patients and controlsThe study included 1110 patients on renal replacement therapy (RRT). They were recruited from 21 dialysis centers located in the Greater Poland region of Poland. The enrollment was started in January, 2009, and finished in May, 2014. All patients were treated with HD on enrollment; however, 28 subjects (2.5%) started RRT with peritoneal dialysis. Subjects dually infected with HBV and HCV or those infected with human immunodeficiency virus were excluded from the study. Of the whole group, 63 patients were HCV-infected (showed antibodies to HCV, anti-HCV) but only 39 of the 63 showed positive for HCV RNA. The remaining 1047 patients were anti-HCV negative, of whom 806 had no history of HBV infection, while 241 were HBV-infected (showed total antibodies to the core antigen of HBV, anti-HBc). In the latter group, 186 subjects developed anti-HBs. HD patient groups are shown in FIGure 1.Subjects were included into th...

show abstract

The Long-term Outcome of Hepatitis B Infection in Hemodialysis Patients

Cited by 50 publications

References 21 publications

Hepatitis B Virus Infection in Dialysis Patients

Hepatitis B Virus Infection in Dialysis Patients

[No Title Available]

Effect of interferon λ3 gene polymorphisms, rs8099917 and rs12979860, on response to hepatitis B virus vaccination and hepatitis B or C virus infections among hemodialysis patients

Contact Info

Product

Resources

About